Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Willow vs Elevated Health

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #429

Willow

Cost-first shoppers who want an oral-tablet GLP-1 option at the same price as the injectable, with no annual commitment.

Visit Willow
VS
Grade C · #430

Elevated Health

Shoppers drawn in by the low first-month price who understand it steps up to a higher recurring rate afterward.

Visit Elevated Health

The verdict

Winner · WillowGrade C vs C

Willow takes it, leading the Cost-Efficiency Index 49 to 48. Willow is a direct-to-consumer telehealth provider offering compounded semaglutide and tirzepatide in both injectable and oral-tablet form at identical prices per format. Elevated Health still earns a CShoppers drawn in by the low first-month price who understand it steps up to a higher recurring rate afterward.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Willow.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

45
40

Price Transparency

54
46

Nationwide Access

24
24

Formulation Options

51
77

Clinical Oversight

79
63

Contract Flexibility

55
53

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecWillowElevated Health
Cost-Efficiency Index49/10048/100
Semaglutide / moNot disclosed$296/mo (all doses, plus a separate fee, compounded)
Tirzepatide / moNot disclosed$359/mo (all doses, compounded)
Semaglutide / yr (modeled)$3,552
Tirzepatide / yr (modeled)$4,308
CoverageCoverage not publishedCoverage not published
Oral / sublingualYesYes
Brand-name accessCompounded onlyCompounded only
Rank here#429#430

Willow

49/100

Where the value is

  • Oral tablet formulations of both semaglutide and tirzepatide, priced identically to the injectable versions ($299/mo and $399/mo respectively) — a genuine format choice most compounded-drug competitors don't offer
  • Month-to-month billing with no prepay or annual term required to get the advertised rate
  • Named physician team publicly listed, including Chief Medical Officer Dr. Michael Green, MD, plus 11+ other credentialed MDs/DOs

The tradeoffs

  • Only 34 states served — notably narrower than WeightlessRx's 49-state footprint; residents of the other 16 states plus DC are excluded
  • Site states medication cost 'varies by dosage and prescription' but never discloses what a higher maintenance dose actually costs beyond the $299/$399 starting figures
Visit Willow

Full Willow review →

Elevated Health

48/100

Where the value is

  • Low, clearly stated first-month price ($196 semaglutide / $259 tirzepatide) with medication, supplies, and expedited shipping included
  • Claims coverage in all 50 states
  • No membership fees and a stated flat price regardless of dose

The tradeoffs

  • The advertised first-month price is not the ongoing price — it steps up to $296/mo (semaglutide) or $359/mo (tirzepatide) starting month 2 unless a multi-month plan is prepaid
  • No oral/tablet GLP-1 option was found anywhere on the current site, despite this being marketed for the brand elsewhere — both featured products are injectable only
Visit Elevated Health

Full Elevated Health review →

Regulatory note: the FDA issued a warning letter to Elevate Your Wellness LLC, dba Elevated in September 2025. We still list and link to Elevated Health; you should know the letter is on the public record before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons